Microcap Ledger Context Therapeutics Inc. $CNTX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Philadelphia, PA
- Fiscal year end
- December 31
- Shares outstanding
- 91,879,177 [10-Q 2026-08-05]
What the company doesAI summary of filing
Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors. The company is advancing three product candidates: CTIM-76 (targeting Claudin 6), which entered Phase 1 trials in January 2025; CT-95 (targeting Mesothelin), which began Phase 1 dosing in April 2025; and CT-202 (targeting Nectin-4), expected to enter Phase 1 trials in the third quarter of 2026. The company is pre-revenue and generates no product sales, instead funding operations through capital financing while pursuing development and potential future commercialization of its pipeline, either independently or through strategic partnerships. [10-K 2026-03-23]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$23.24M | −$18.45M | $42.99M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | — | −$36.12M | −$26.39M | $66.00M | [10-K 2026-03-23] |
| FY ended Dec 2024 | — | −$26.73M | −$14.56M | $94.43M | [10-K 2026-03-23] |
- Quarterly cash burn
- −$9.22M
- Cash runway Estimate
- ~14 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 74,998,312 | [10-Q 2024-11-06] |
| 2025-03-18 | 89,704,194 | [10-K 2025-03-20] |
| 2025-05-05 | 89,704,194 | [10-Q 2025-05-07] |
| 2025-08-04 | 89,704,194 | [10-Q 2025-08-06] |
| 2025-11-04 | 91,879,177 | [10-Q 2025-11-05] |
| 2026-03-19 | 91,879,177 | [10-K 2026-03-23] |
| 2026-05-04 | 91,879,177 | [10-Q 2026-05-06] |
| 2026-08-03 | 91,879,177 | [10-Q 2026-08-05] |
- Shelf registration
- S-3 filed 2024-11-06; declared effective 2024-11-14 [S-3 2024-11-06]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-31. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-31 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-31] |
| 2025-09-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-09-02] |
| 2025-02-28 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-28] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-05 | 8-K | Regulation FD disclosure |
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-07-31 | 8-K | Listing notice or transfer |
| 2026-07-31 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-27 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-26 | 8-K | Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-06-15 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-18 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $CNTX
Email me when Context Therapeutics Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.